Centpyraquin
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Centpyraquin, also known as IHCH-7162 or as compound 69-183, is a serotonin receptor modulator related to the partial ergolines and phenylpiperazines.[1][2] It is a serotonin 5-HT1A receptor agonist and a mixed modulator of the serotonin 5-HT2A receptor, acting as a weak partial agonist of G protein signaling and as an antagonist of β-arrestin2 recruitment.[2] The drug has antipsychotic-like, CNS depressant, and antihypertensive effects in animals.[3][4][5][6] Centpyraquin was developed by researchers in India and first described by the 1970s[1][3][4][5][6] before being studied and described further in 2024.[2]
Other namesIHCH-7162; IHCH7162; Compound 69-183
Drug classSerotonin 5-HT1A receptor agonist; Serotonin 5-HT2A receptor weak partial agonist or antagonist; Antipsychotic; Antihypertensive agent
ATC code
- None
 | |
| Clinical data | |
|---|---|
| Other names | IHCH-7162; IHCH7162; Compound 69-183 |
| Drug class | Serotonin 5-HT1A receptor agonist; Serotonin 5-HT2A receptor weak partial agonist or antagonist; Antipsychotic; Antihypertensive agent |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H25FN2O |
| Molar mass | 352.453 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
